Nasdaq
$146.10▲ 0.74%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.52BShares out 51.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.3After-hours26.09.04 08:094Ownership#●●●
Axsome Therapeutics, Inc.
Insider Mark L. Jacobson of Axsome Therapeutics filed a Form 4 on September 3, 2026, reporting changes in beneficial ownership of securities. This filing serves as a routine disclosure of insider activity and does not indicate any material changes to the company's capital structure or control.…more
$146.10+0.74%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.3After-hours26.09.04 06:43144Ownership
Axsome Therapeutics, Inc.
Axsome Therapeutics insider Mark L. Jacobson has filed an SEC Form 144 to report a proposed sale of company securities. This is a standard disclosure regarding an insider's plan to dispose of shares.…more
$146.10+0.74%vs prev closeView filingShare - 8.10After-hours26.08.11 05:0710-QEarnings
Axsome Therapeutics, Inc.
Axsome Therapeutics는 2026년 6월 26일 Blackstone과의 기존 대출 계약을 수정하여 회전 신용 공여 한도를 기존 7,000만 달러에서 9,000만 달러로 2,000만 달러 증액했습니다. 이번 계약 수정으로 회사는 추가 유동성을 확보하게 되었으며, 관련 비용으로 2,500달러의 수정 수수료를 지급했습니다.…more
$146.10+0.74%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 20:00#●●●#●●●
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2…more
Axsome Therapeutics announced it will report its financial results for the third quarter of 2026 on November 2, before the market opens. Following the release, management will host a conference call to discuss the results and provide a business update.…more
$146.10+0.74%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.21Pre-market26.09.21 20:00
●●●●●●●● ●●●●● ●●●●●●
Axsome Therapeutics announced findings from a survey highlighting the significant impact of agitation symptoms on Alzheimer's patients and their caregivers. This release serves as an awareness initiative and contains no direct financial or clinical data that would impact the stock price.…more
$146.10+0.74%vs prev close - 9.17Pre-market26.09.17 20:07
●●●●●●●● ●●●●● ●●●●●●
Axsome Therapeutics announced it will present new clinical data regarding major depressive disorder and Alzheimer's disease agitation at Psych Congress 2026. As this is a presentation of data rather than a regulatory approval or financial milestone, the impact remains neutral.…more
$146.10+0.74%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report